Evaluation of the Role of Gabapentin and/or Omega-3 in Uremic Pruritus for Patients Undergoing Hemodialysis

2018 ◽  
Vol 9 (SPL1) ◽  
Author(s):  
Sinan Forat Hussein ◽  
Kadhim Ali Kadhim ◽  
Ali JassimAl Sultani ◽  
Saad Abdulrahman Hussain
Keyword(s):  
Renal Disease ◽  
Fish Oil ◽  
End Stage Renal Disease ◽  
Serum Levels ◽  
Efficacy And Safety ◽  
Omega 3 ◽  
Uremic Pruritus ◽  
Stage Renal Disease ◽  
End Stage

Uremic pruritus is chronic itching that occurs in patients with advanced or end-stage renal disease. It is one of common symptoms in patients with end-stage renal disease with approximately 60–90% of patients on hemodialysis (HD) suffering from this problem. This study was designed to evaluate the efficacy and safety of prescribing Gabapentin or Omega-3 alone or in combination for relieving uremic pruritus in Iraqi patients undergoing hemodialysis. The results showed that all the three involved regimens (gabapentin,omega-3,and the combination of both drugs) had significantly reduced the pruritus score. Furthermore,the combination was significantly superior to other regimens in reducing pruritus score,while no significant effect was observed by all the regimens on interleukin-6 or on parathyroid hormone serum levels. In Conclusion Gabapentin 100mg plus 1000mg omega-3 based fish oil capsules containing 120mg is superior to gabapentin 100mg capsule or 1g of omega-3 based fish oil capsule containing 120mg docosahexaenoic acid and 180mg ecosapentaenoic acid (each alone),in reducing pruritus score in a sample of Iraqi patients.

Could Antioxidant Supplementation Delay Progression of Cardiovascular Disease in End-Stage Renal Disease Patients?

2020 ◽  
Vol 19 (1) ◽  
pp. 41-54 ◽  
Author(s):  
Stefanos Roumeliotis ◽  
Athanasios Roumeliotis ◽  
Xenia Gorny ◽  
Peter R. Mertens
Keyword(s):  
Oxidative Stress ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Close Association ◽  
Omega 3 ◽  
Endstage Renal Disease ◽  
Increased Risk ◽  
Underlying Mechanisms ◽  
Stage Renal Disease ◽  
End Stage

In end-stage renal disease patients, the leading causes of mortality are of cardiovascular (CV) origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. A contributing role of oxidative stress is postulated, which is increased even at early stages of chronic kidney disease, is gradually augmented in parallel to progression to endstage renal disease and is further accelerated by renal replacement therapy. Oxidative stress ensues when there is an imbalance between reactive pro-oxidants and physiologically occurring electron donating antioxidant defence systems. During the last decade, a close association of oxidative stress with accelerated atherosclerosis and increased risk for CV and all-cause mortality has been established. Lipid peroxidation has been identified as a trigger for endothelial dysfunction, the first step towards atherogenesis. In order to counteract the deleterious effects of free radicals and thereby ameliorate, or delay, CV disease, exogenous administration of antioxidants has been proposed. Here, we attempt to summarize existing data from studies that test antioxidants for CV protection, such as vitamins E and C, statins, omega-3 fatty acids and N-acetylcysteine.

Recent Advances in the Management of the Infant, Child, and Adolescent With Chronic Renal Failure

1990 ◽  
Vol 11 (9) ◽  
pp. 277-282
Author(s):  
Richard N. Fine
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Quarter Century ◽  
Irreversible Reduction ◽  
Age Limits ◽  
Stage Renal Disease ◽  
End Stage

The prognosis of the infant, child, or adolescent with chronic renal failure, defined as an irreversible reduction in glomerular filtration rate, has improved during the past quarter century because of the use of dialysis and renal transplantation. These have prolonged lives in previously fatal situations. Because the potential not only to sustain life but also to effect full rehabilitation exists with the introduction of these treatments, it is now imperative that the multisystem consequences of uremia be either minimized or totally avoided in the pediatric patient with chronic renal failure. The role of the pediatrician in managing the infant, child, or adolescent with chronic renal failure should be directed toward minimizing the potentially devastating consequences of uremia so that the patient is in optimal clinical condition when end stage renal disease occurs. INCIDENCE It is difficult to know the incidence and prevalence of chronic renal failure and end stage renal disease in children. Surveys in Europe and North America have been conducted to obtain precise information regarding these issues; not only have the definitions included in these surveys differed, but the upper and lower age limits defining pediatric patients have not been uniform. The available data suggest a prevalence of chronic renal failure of 18.5 per 1 million child population and an incidence of end stage renal disease of from 3 to 6 children per 1 million total population.

scholarly journals The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone

2019 ◽  
Vol 31 (3) ◽  
pp. 515-524
Author(s):  
T. T. Jansz ◽  
N. A. Goto ◽  
A. J. van Ballegooijen ◽  
H. C. Willems ◽  
M. C. Verhaar ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Renal Disease ◽  
Vertebral Fractures ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

Effects of Dietary Manipulation with Fish Oil on Platelet Receptors for von Willebrand Factor and Fibrinogen in Patients with End-Stage Renal Disease

Nephron ◽  
1995 ◽  
Vol 69 (2) ◽  
pp. 170-170 ◽  
Author(s):  
Mario Liani ◽  
Ettore Tresca ◽  
Giuseppe Nubile ◽  
Filippo Salvati ◽  
Pierre Trolliet ◽  
...  
Keyword(s):  
Renal Disease ◽  
Fish Oil ◽  
Von Willebrand Factor ◽  
End Stage Renal Disease ◽  
Dietary Manipulation ◽  
Platelet Receptors ◽  
Stage Renal Disease ◽  
End Stage ◽  
Von Willebrand ◽  
Willebrand Factor
Sign in / Sign up

Export Citation Format

Share Document